Aging
 Submit an Article
Online ISSN: 1945-4589
  • Home
  • Search
  • Navigate
  • Home
  • Editorial Board
  • Editorial Policies
  • Advance Publications
  • Current Issue
  • Archive
  • Special Collections
  • Scientific Integrity
  • Publication Ethics Statements
  • Interviews with Outstanding Authors
  • Newsroom
  • Sponsored Conferences
  • Contact
Rapamycin Press LLC is the publisher of Aging: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
Learn about our FREE Post-Publication Promotion Services
Longevity & Aging Series
Longevity and Aging
ARDD 2025
Aging Research and Drug Discovery Meeting (ARDD)
Aging Initiative at Harvard
Aging Initiative at Harvard

Search

To search the journal, enter a term in the search bar. If you'd like to find specific authors, titles, or abstracts, use the advanced search to the right.

Search Results

1 results found. Results per page: [ 20 ][ 40 ][ 60 ][ 80 ][ 100 ][ 200 ][ 300 ]

Sort by: [ Publication Date ][ Score ]

Year of publication: [ 2025 ][ 2024 ][ 2023 ][ 2022 ][ 2021 ][ 2020 ][ 2019 ][ 2018 ][ 2017 ][ 2016 ][ 2015 ][ 2014 ][ 2013 ][ 2012 ][ 2011 ][ 2010 ][ 2009 ][ Any ]

Direction: [ Desc ][ Asc ]

  • Research Paper pp undefined-undefined

    Solamargine acts as an antiviral by interacting to MZF1 and targeting the core promoter of the hepatitis B virus gene

    Relevance score: 6.6481166
    Wenwen Chen, Xinrui Zhao, Yingli Huang, Kai Lu, Yuan Li, Xiaofang Li, Hui Ding, Xiuling Li, Suofeng Sun
    Keywords: hepatitis B virus, Solamargine, core promoter, MZF1, anti-HBV activity
    Published in Aging on Invalid Date
    Show abstract
    Hide abstract

    Background: Hepatitis B virus (HBV) infection is still a serious threat to global health and can lead to a variety of liver diseases, including acute and chronic hepatitis, liver cirrhosis, liver failure, hepatocellular carcinoma (HCC), and so on. At present, there are mainly two kinds of drugs for the treatment of hepatitis B at home and abroad: interferon (IFN) and nucleoside/nucleotide analogs (NAs). In recent years, natural compounds have been considered an important source for the development of new anti-HBV drugs due to their complex structure, diverse components, high efficiency, and low toxicity. Many studies have demonstrated that Solamargine has significant anticancer activity, but the antiviral effect is rarely studied. This study aimed to verify the anti-HBV effect of Solamargine and to explore the specific mechanism.

    Method: The relative expression of HBV pregenomic RNA (pgRNA) was detected by reverse transcription real-time fluorescence quantitative PCR (RT-qPCR). Northern blot and western blot were used to detect the relative expression of HBV pgRNA and target protein. PCR was used in the construction of HBV pg-promoter, ENII/BCP, and a series of gene deletion mutant fluorescent reporter vectors. The fluorescence relative expression of each mutant was detected by Renilla luciferase assay.

    Results: By binding to MZF1 (Myeloid zinc finger protein 1, MZF1), Solamargine inhibits HBV core promoter activity, reduces pregenomic RNA level, and inhibits HBV, achieving antiviral effects.

Advanced Search

Home | Editorial Board | Editorial Policies | Advance Publications | Current Issue | Archive | Special Collections | Scientific Integrity | Publication Ethics Statements | Interviews with Outstanding Authors | Newsroom | Sponsored Conferences | Contact

By using our site you are giving us permission to use cookies. This website collects cookies to deliver a better user experience, and to analyze our website traffic and performance. Personal data is not collected. Privacy Policy | Terms Of Service

Copyright © 2025 Rapamycin Press LLC dba Impact Journals
Impact Journals ® is a registered trademark of Rapamycin Press LLC